title: Suppression of Allograft Rejection with Soluble VEGF Receptor 2 Chimeric Protein in a Mouse Model of Corneal Transplantation.
abstract: When a transparent cornea becomes opaque due to infectious diseases, trauma, or ophthalmic surgery, the impaired cornea is replaced with a donor cornea to improve visual function. In this corneal transplantation, the graft survival rate is comparatively high, partly because of lacking vascular and lymphatic vessel in cornea. However, the transplanted corneas sometimes become opaque if allograft rejection occurs. Suppression of allograft rejection is critical for favorable outcomes of corneal transplantation. The essential effects of endogenous monomeric soluble vascular endothelial growth factor receptors (VEGFRs) 1 and 2 have been reported in corneal angiogenesis and lymphangiogenesis. This study investigated the effects of dimeric soluble VEGFR2/Fc chimera protein on corneal allograft rejection for future clinical application. Allogeneic full-thickness corneal transplantation was performed in C57BL/6 to BALB/c mice. The recipients were treated by intrastromal injection of soluble VEGFR1/Fc chimera (sR1/Fc group), soluble VEGFR2/Fc chimera (sR2/Fc group), or human IgG1/Fc protein (IgG/Fc group) at 0, 7, and 14 days after surgery. Both hemangiogenesis and lymphangiogenesis were significantly suppressed in the corneas of the sR2/Fc group compared with the IgG/Fc group. All grafts failed due to corneal wound rupture in the sR1/Fc group. In the sR2/Fc group, respective donor-derived MHC class II(+)/CD11c(+) cells and CD11b-positive macrophage infiltration were reduced in the DLNs and the corneas showing a negative delayed-type hypersensitivity, compared with the IgG/Fc group. Our findings demonstrate that soluble VEGFR2/Fc chimera protein efficiently suppresses corneal allo-rejection, while reducing hemangiogenesis and lymhangiogenesis, and immune-competent cell-trafficking and may be a powerful tool for corneal allograft survival.
authors.affiliation: Department of Ophthalmology, Yokohama Minami Kyosai Hospital.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Hayashi
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Usui
authors.forename: Satoru
authors.initials: S
authors.lastname: Yamagami
mesh_terms: D064591:Allografts; D000818:Animals; D003316:Corneal Diseases / Q000276:immunology* / Q000601:surgery; D016039:Corneal Transplantation / Q000009:adverse effects; D004195:Disease Models, Animal; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control*; D008297:Male; D051379:Mice; D009389:Neovascularization, Pathologic; D012995:Solubility; D014184:Transplantation, Homologous; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*
chemical_list: D040301:Vascular Endothelial Growth Factor Receptor-2